ALKS Price Prediction Next Week
Analysis and Insights
To predict the stock price of Alkermes (ALKS) for the next trading week, we analyze both technical indicators and recent news sentiment.
Technical Analysis:
The stock is currently trading at $35.09, with a 52-week high of $33.73 and a low of $22.90. Recent price action shows a bullish trend, with the stock crossing above the 50-day moving average. Key technical indicators suggest a potential upside:
- MACD: Bullish crossover signal.
- RSI: 60, indicating the stock is not overbought.
- Support/Resistance: Immediate resistance at $38, with support at $34.
News Sentiment and Fundamental Analysis:
- Earnings Beat: Alkermes reported strong Q4 2024 earnings, with EPS of $1.04 beating estimates of $0.76.
- Analyst Ratings: The average price target is $39.30, with a high of $43 and a low of $21, indicating varied analyst opinions.
- Insider Activity: Insider selling has increased, with 14 sales in the last six months, potentially signaling caution.
Price Prediction:
Based on technical indicators and positive earnings momentum, ALKS is expected to reach $38.00 in the next trading week. The stock shows bullish potential but with volatility risks.
Recommendation:
Buy ALKS with a target price of $38.00 and a stop-loss at $34.00.
ALKS Similar Chart Price Prediction
The price of ALKS is predicted to go up 2.38%, based on the high correlation periods with THR. The similarity of these two price pattern on the periods is 97.3%.
ALKS
THR
Up: 2.38%Similarity: 97.3%
ALKS Revenue Forecast
ALKS EPS Forecast
ALKS FAQs
What is ALKS revenue forecast for next quarter？
What is ALKS eps forecast for next quarter？
ALKS Analyst's Forecast
Leonid Timashev
RBC Capital
Hold
2025-03-13
Price Target
$40
Upside
+18.98%
RBC Capital initiated coverage of Alkermes with a Sector Perform rating and $40 price target. The company's next-generation orexin has a "potentially best-in-class profile" and over $1.5B in sales, and it could provide visibility to longer-term growth for Alkermes, the analyst tells investors in a research note. However, the firm says that with success largely expected in the "increasingly crowded" narcolepsy space, it waits for more de-risking data to better benchmark what the peak opportunity could be. RBC believes Alkermes shares fairly reflect the balance of its near-term earnings pressure against a potential long-term multi-billion opportunity.
Chris Shibutani
Goldman Sachs
Strong Buy
2025-02-14
Price Target
$30 → $32
Downside
-10.94%
David Hoang
Deutsche Bank
Strong Buy
2025-02-11
Price Target
$40
Upside
+25.83%
